Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2022 U.S. Biopharma Recap

An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Why Now Could Be the Time to Revisit Consumer Packaged Goods Stocks

    Valuations are compressed, sentiment is weak, and catalysts are building. Could consumer packaged goods stocks be ready for a comeback?

    Read more

  • Economics Weekly: Record Margins, the AI Capex Cycle, and the Warning Signs to Monitor

    In this Economics Weekly, Richard de Chazal examines the quality of today’s earnings, assesses where we are in the AI capex cycle, and identifies the signals that would suggest the recovery is becoming more fragile.

    Read more

  • Blackstone Has Agreed to Acquire Flow Control Holdings

    William Blair acted as financial advisor to Blackstone in connection with its pending acquisition of Flow Control Holdings from Audax Private Equity.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures